Rxfp1 receptor agonists

A compound of the formula:

• wherein:
• Ring A is a group of the formula
• wherein each of
• is optionally substituted by one or more substituents selected from halogens, —CN, C1-4 alkyl, —S—C1-3 alkyl, and C1-3 alkoxy, wherein each C1-4 alkyl and C1-3 alkoxy is independently optionally substituted by one or more substituents selected from halogens and —CN;
• —Y— is a C1-3 alkylene;
• —G6— is —C(R1)— or —N—;
• R1 is C1-3 alkoxy;
• R2 is —OCH2COOH or an N-linked 4-7 membered heterocycle;
• wherein the N-linked 4-7 membered heterocycle is selected from an azetidine, pyrrolidine, morpholine, piperazine, piperidine, and oxazepane;
• wherein the heterocycle is optionally bridged by, fused with, or spiro-linked with a C1-4 alkylenyl, or a 1-5 membered heteroalkyl;
• wherein the heterocycle, the C1-4 alkylenyl, and the 1-5 membered heteroalkyl are each optionally substituted with 1-3 substituents each independently selected from halogen, oxo, C1-4 alkyl, C1-4 haloalkyl, —OH, and —COOH;
• R3 is selected from the group consisting of
• wherein
• is optionally substituted with one to three halogens;
• —G4— is —CH— or —N—;
• —G5— is —CH2— or —O—;
• R3a, at each occurrence, is independently —H, halogen, —SF5, —SO2CF3, —SCF3, —CN, C1-4 alkyl, C3-6 cycloalkyl, or C1-3 alkoxy, wherein the C1-4 alkyl and C1-3 alkoxy are optionally substituted with one, two or three halogens;
• R3b is independently —H, halogen, difluoromethyl, trifluoromethyl, methoxy, trifluoromethoxy, —CN, or C1-4 alkyl;
• R3c, at each occurrence, is independently —H or halogen;
• R3d is —H, halogen, —CN, C1-4 alkyl, C3-6 cycloalkyl, or C1-3 alkoxy, wherein the C1-4 alkyl and C1-3 alkoxy are optionally substituted with one, two, or three halogens;
• or a pharmaceutically acceptable salt thereof.